| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Erythrocytes | 20 | 2005 | 206 | 1.610 |
Why?
|
| Glycolates | 6 | 2005 | 12 | 1.110 |
Why?
|
| Ethylene Glycols | 6 | 2005 | 7 | 0.970 |
Why?
|
| Hemolysis | 9 | 2005 | 105 | 0.870 |
Why?
|
| Anemia, Sickle Cell | 14 | 2011 | 334 | 0.750 |
Why?
|
| Hematology | 2 | 2012 | 38 | 0.610 |
Why?
|
| Erythrocytes, Abnormal | 7 | 2011 | 18 | 0.460 |
Why?
|
| Solvents | 2 | 2005 | 42 | 0.420 |
Why?
|
| Erythrocyte Inclusions | 1 | 2012 | 2 | 0.400 |
Why?
|
| Clinical Clerkship | 4 | 2009 | 90 | 0.340 |
Why?
|
| Endothelium, Vascular | 5 | 2011 | 516 | 0.310 |
Why?
|
| Space Flight | 5 | 1997 | 115 | 0.300 |
Why?
|
| Erythropoiesis | 5 | 1997 | 40 | 0.300 |
Why?
|
| Hemolysin Proteins | 1 | 2005 | 31 | 0.240 |
Why?
|
| Erythrocyte Deformability | 2 | 1994 | 3 | 0.230 |
Why?
|
| Carcinogens | 1 | 2004 | 153 | 0.220 |
Why?
|
| Cytoplasmic Granules | 1 | 2004 | 47 | 0.220 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2005 | 37 | 0.210 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 146 | 0.200 |
Why?
|
| Endothelin-1 | 1 | 2002 | 39 | 0.200 |
Why?
|
| Epoprostenol | 1 | 2002 | 67 | 0.190 |
Why?
|
| Physical Examination | 1 | 2001 | 165 | 0.180 |
Why?
|
| Rats | 6 | 2005 | 3668 | 0.170 |
Why?
|
| Internal Medicine | 3 | 2009 | 148 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 306 | 0.160 |
Why?
|
| Blood Volume | 3 | 1996 | 80 | 0.160 |
Why?
|
| Hemoglobins, Abnormal | 1 | 1999 | 13 | 0.160 |
Why?
|
| Endothelium | 3 | 1987 | 72 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 1999 | 82 | 0.150 |
Why?
|
| Calcium | 5 | 2005 | 1098 | 0.150 |
Why?
|
| Anemia, Aplastic | 2 | 1997 | 59 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2005 | 1690 | 0.140 |
Why?
|
| Fasciitis | 1 | 1997 | 20 | 0.140 |
Why?
|
| History, 20th Century | 2 | 2012 | 381 | 0.140 |
Why?
|
| Rats, Inbred F344 | 3 | 2005 | 105 | 0.130 |
Why?
|
| Cell Adhesion | 7 | 2011 | 318 | 0.130 |
Why?
|
| Humans | 50 | 2024 | 123280 | 0.130 |
Why?
|
| Osmotic Fragility | 3 | 2003 | 5 | 0.130 |
Why?
|
| Eosinophilia | 1 | 1997 | 101 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2004 | 3341 | 0.120 |
Why?
|
| Physician Executives | 3 | 2009 | 40 | 0.120 |
Why?
|
| Adult | 23 | 2021 | 29091 | 0.120 |
Why?
|
| Spherocytosis, Hereditary | 1 | 1994 | 8 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 805 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 4299 | 0.110 |
Why?
|
| Erythrocyte Aging | 4 | 1997 | 8 | 0.110 |
Why?
|
| Acetylcysteine | 1 | 2013 | 73 | 0.110 |
Why?
|
| Animals | 9 | 2012 | 33850 | 0.100 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2013 | 54 | 0.100 |
Why?
|
| Hemoglobin SC Disease | 2 | 1999 | 12 | 0.100 |
Why?
|
| France | 1 | 2012 | 78 | 0.100 |
Why?
|
| Bone Marrow | 4 | 1997 | 326 | 0.100 |
Why?
|
| History, 19th Century | 1 | 2012 | 116 | 0.100 |
Why?
|
| Erythrocyte Membrane | 2 | 2011 | 23 | 0.100 |
Why?
|
| Sulfoglycosphingolipids | 1 | 2011 | 8 | 0.090 |
Why?
|
| Male | 24 | 2021 | 60345 | 0.090 |
Why?
|
| Sickle Cell Trait | 2 | 1987 | 11 | 0.090 |
Why?
|
| Hematocrit | 3 | 2001 | 112 | 0.090 |
Why?
|
| Species Specificity | 2 | 2005 | 550 | 0.080 |
Why?
|
| Erythrocyte Indices | 5 | 2003 | 14 | 0.080 |
Why?
|
| Specialty Boards | 1 | 2009 | 19 | 0.080 |
Why?
|
| Achievement | 1 | 2009 | 32 | 0.080 |
Why?
|
| Licensure, Medical | 1 | 2009 | 24 | 0.080 |
Why?
|
| Interleukin-1 | 2 | 2002 | 143 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 3 | 2000 | 577 | 0.070 |
Why?
|
| Lutheran Blood-Group System | 1 | 1987 | 1 | 0.070 |
Why?
|
| Cations | 2 | 2002 | 39 | 0.070 |
Why?
|
| Cells, Cultured | 5 | 2002 | 3045 | 0.070 |
Why?
|
| Histiocytes | 1 | 1986 | 23 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 2002 | 967 | 0.070 |
Why?
|
| Typhoid Fever | 1 | 1986 | 19 | 0.070 |
Why?
|
| Erythropoietin | 3 | 1996 | 104 | 0.070 |
Why?
|
| Pancytopenia | 1 | 1986 | 40 | 0.070 |
Why?
|
| Middle Aged | 13 | 2021 | 26095 | 0.070 |
Why?
|
| Phagocytosis | 1 | 1986 | 165 | 0.060 |
Why?
|
| Female | 19 | 2021 | 65628 | 0.060 |
Why?
|
| Splenic Infarction | 1 | 1985 | 4 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 176 | 0.060 |
Why?
|
| Plasma Cells | 1 | 2005 | 54 | 0.060 |
Why?
|
| Microscopy, Phase-Contrast | 2 | 2002 | 20 | 0.060 |
Why?
|
| Potassium Channel Blockers | 1 | 2005 | 84 | 0.060 |
Why?
|
| Carcinogenicity Tests | 1 | 2004 | 20 | 0.060 |
Why?
|
| Cocarcinogenesis | 1 | 2004 | 23 | 0.060 |
Why?
|
| Kupffer Cells | 1 | 2004 | 19 | 0.060 |
Why?
|
| Inhalation Exposure | 1 | 2004 | 36 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2005 | 328 | 0.060 |
Why?
|
| Hemangiosarcoma | 1 | 2004 | 38 | 0.060 |
Why?
|
| Spleen | 1 | 1985 | 272 | 0.060 |
Why?
|
| Spherocytes | 1 | 2003 | 2 | 0.060 |
Why?
|
| Hemoglobin C Disease | 1 | 2003 | 3 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 312 | 0.060 |
Why?
|
| Anemia, Sideroblastic | 1 | 2004 | 17 | 0.060 |
Why?
|
| Hypotonic Solutions | 1 | 2003 | 15 | 0.060 |
Why?
|
| Curriculum | 1 | 2009 | 716 | 0.060 |
Why?
|
| Dermatan Sulfate | 1 | 2003 | 4 | 0.060 |
Why?
|
| beta-Thalassemia | 1 | 2003 | 28 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 212 | 0.050 |
Why?
|
| Chondroitin Sulfates | 1 | 2003 | 14 | 0.050 |
Why?
|
| Heparitin Sulfate | 1 | 2003 | 20 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 2 | 2005 | 669 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 169 | 0.050 |
Why?
|
| Densitometry | 1 | 2002 | 25 | 0.050 |
Why?
|
| Time Factors | 4 | 2004 | 6223 | 0.050 |
Why?
|
| Filtration | 1 | 2002 | 23 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2000 | 63 | 0.050 |
Why?
|
| Career Mobility | 1 | 2003 | 51 | 0.050 |
Why?
|
| Cell Size | 1 | 2002 | 81 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2004 | 671 | 0.050 |
Why?
|
| Kinetics | 2 | 2002 | 1317 | 0.050 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2002 | 10 | 0.050 |
Why?
|
| United States | 4 | 2012 | 10655 | 0.050 |
Why?
|
| Hemorheology | 1 | 2002 | 28 | 0.050 |
Why?
|
| Weightlessness | 3 | 1997 | 44 | 0.050 |
Why?
|
| Carboxyhemoglobin | 1 | 2001 | 6 | 0.050 |
Why?
|
| Lymphoma | 1 | 2005 | 322 | 0.050 |
Why?
|
| Heparin | 1 | 2003 | 227 | 0.050 |
Why?
|
| Plasma Volume | 3 | 1996 | 15 | 0.050 |
Why?
|
| Hospitals, County | 1 | 2021 | 23 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 226 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 1996 | 804 | 0.050 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2001 | 11 | 0.050 |
Why?
|
| Remission Induction | 1 | 2002 | 299 | 0.050 |
Why?
|
| DNA Damage | 1 | 2004 | 513 | 0.050 |
Why?
|
| Prekallikrein | 1 | 1980 | 1 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 1989 | 866 | 0.050 |
Why?
|
| Kallikreins | 1 | 1980 | 26 | 0.050 |
Why?
|
| Leukemia, Lymphoid | 1 | 1980 | 108 | 0.050 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 51 | 0.040 |
Why?
|
| HIV Infections | 2 | 2003 | 1860 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 137 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2000 | 35 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2000 | 77 | 0.040 |
Why?
|
| Calmodulin | 1 | 2001 | 230 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 294 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1231 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 140 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2001 | 158 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 133 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 1980 | 99 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2001 | 747 | 0.040 |
Why?
|
| Platelet Count | 2 | 2013 | 135 | 0.040 |
Why?
|
| Erythroid Precursor Cells | 2 | 1997 | 24 | 0.040 |
Why?
|
| von Willebrand Factor | 2 | 1993 | 196 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2001 | 323 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2001 | 348 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2003 | 580 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2004 | 538 | 0.040 |
Why?
|
| Blood Platelets | 2 | 1995 | 327 | 0.040 |
Why?
|
| Conjugation, Genetic | 1 | 1978 | 9 | 0.040 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1997 | 3 | 0.040 |
Why?
|
| Education, Medical | 1 | 2001 | 289 | 0.040 |
Why?
|
| Erythrocyte Volume | 1 | 1997 | 4 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 1978 | 134 | 0.040 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1997 | 28 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1997 | 25 | 0.040 |
Why?
|
| Adrenal Insufficiency | 1 | 1997 | 29 | 0.030 |
Why?
|
| Bone Marrow Cells | 2 | 1996 | 261 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6390 | 0.030 |
Why?
|
| Aged | 5 | 2021 | 19180 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2000 | 495 | 0.030 |
Why?
|
| Isoantibodies | 1 | 1996 | 70 | 0.030 |
Why?
|
| Iron | 2 | 1996 | 262 | 0.030 |
Why?
|
| Reticulocyte Count | 1 | 1995 | 2 | 0.030 |
Why?
|
| Pain | 1 | 1999 | 470 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 1996 | 123 | 0.030 |
Why?
|
| Cell Cycle | 1 | 1978 | 618 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 1995 | 69 | 0.030 |
Why?
|
| Hemoglobin, Sickle | 1 | 1995 | 21 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1978 | 424 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 1995 | 171 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2000 | 532 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 1312 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 1236 | 0.030 |
Why?
|
| Adolescent | 3 | 2021 | 19126 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1997 | 364 | 0.030 |
Why?
|
| ADAMTS13 Protein | 1 | 2013 | 62 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2013 | 79 | 0.030 |
Why?
|
| Rheology | 2 | 1996 | 31 | 0.030 |
Why?
|
| Intracellular Fluid | 1 | 1992 | 24 | 0.020 |
Why?
|
| Mice | 2 | 2011 | 17555 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 1218 | 0.020 |
Why?
|
| Canada | 2 | 2003 | 293 | 0.020 |
Why?
|
| Oxygen | 1 | 1995 | 550 | 0.020 |
Why?
|
| Sulfotransferases | 1 | 2011 | 27 | 0.020 |
Why?
|
| Adaptation, Physiological | 3 | 1997 | 261 | 0.020 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2011 | 29 | 0.020 |
Why?
|
| Water | 1 | 1992 | 182 | 0.020 |
Why?
|
| Single-Chain Antibodies | 1 | 2011 | 43 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2011 | 73 | 0.020 |
Why?
|
| Mutation | 1 | 2004 | 5765 | 0.020 |
Why?
|
| Apoptosis | 1 | 1997 | 1787 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 1686 | 0.020 |
Why?
|
| Preceptorship | 1 | 2009 | 33 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2009 | 72 | 0.020 |
Why?
|
| Oligopeptides | 2 | 2001 | 117 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1992 | 458 | 0.020 |
Why?
|
| Career Choice | 1 | 2009 | 142 | 0.020 |
Why?
|
| Blood Circulation | 1 | 1987 | 22 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 8870 | 0.020 |
Why?
|
| Videotape Recording | 1 | 1987 | 57 | 0.020 |
Why?
|
| Receptors, Mitogen | 1 | 1987 | 4 | 0.020 |
Why?
|
| Aging | 1 | 1994 | 1185 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1987 | 120 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2003 | 3553 | 0.020 |
Why?
|
| Cell Communication | 1 | 1987 | 165 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1987 | 121 | 0.020 |
Why?
|
| Faculty, Medical | 1 | 2009 | 260 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 1995 | 1010 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 1987 | 245 | 0.020 |
Why?
|
| Hyperplasia | 1 | 1986 | 209 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2771 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 1987 | 449 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2005 | 15 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 12176 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 427 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 113 | 0.020 |
Why?
|
| Herpesvirus 8, Human | 1 | 2005 | 49 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1985 | 151 | 0.010 |
Why?
|
| Splenomegaly | 1 | 1985 | 34 | 0.010 |
Why?
|
| Umbilical Veins | 2 | 1996 | 71 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 172 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 471 | 0.010 |
Why?
|
| Atrophy | 1 | 1985 | 226 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 2696 | 0.010 |
Why?
|
| Hemoglobin C | 1 | 2003 | 2 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 479 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 3868 | 0.010 |
Why?
|
| Homosexuality | 1 | 2003 | 18 | 0.010 |
Why?
|
| Reed-Sternberg Cells | 1 | 2003 | 7 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 16081 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 420 | 0.010 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2003 | 67 | 0.010 |
Why?
|
| Pedigree | 1 | 1987 | 1581 | 0.010 |
Why?
|
| Vinblastine | 1 | 2003 | 48 | 0.010 |
Why?
|
| Antithrombins | 1 | 2003 | 56 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3734 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2003 | 193 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 105 | 0.010 |
Why?
|
| Dacarbazine | 1 | 2003 | 86 | 0.010 |
Why?
|
| Authorship | 1 | 2003 | 29 | 0.010 |
Why?
|
| Bleomycin | 1 | 2003 | 150 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 266 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2003 | 63 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2009 | 973 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2003 | 2058 | 0.010 |
Why?
|
| Fibronectins | 2 | 1996 | 102 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 335 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 289 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2003 | 355 | 0.010 |
Why?
|
| Reticulocytes | 1 | 2001 | 42 | 0.010 |
Why?
|
| Awards and Prizes | 1 | 2003 | 63 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 546 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 532 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1981 | 9 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2003 | 300 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 1581 | 0.010 |
Why?
|
| Heterozygote | 1 | 2003 | 678 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2003 | 266 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2001 | 52 | 0.010 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2001 | 13 | 0.010 |
Why?
|
| Physician's Role | 1 | 2003 | 165 | 0.010 |
Why?
|
| Bilirubin | 1 | 2001 | 121 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 717 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 139 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2001 | 164 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 4692 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2000 | 37 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 409 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2000 | 40 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2000 | 78 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2001 | 892 | 0.010 |
Why?
|
| Karyotyping | 1 | 2000 | 330 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2000 | 127 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 1063 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 1012 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 1236 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 1211 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1414 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2001 | 528 | 0.010 |
Why?
|
| Thrombosis | 1 | 2003 | 518 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 1289 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 756 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2000 | 351 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1997 | 22 | 0.010 |
Why?
|
| Abortion, Habitual | 1 | 1997 | 18 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1996 | 18 | 0.010 |
Why?
|
| Protein Binding | 1 | 2001 | 1741 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 2053 | 0.010 |
Why?
|
| Chromium Radioisotopes | 1 | 1996 | 4 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1996 | 43 | 0.010 |
Why?
|
| Receptors, Vitronectin | 1 | 1996 | 4 | 0.010 |
Why?
|
| E-Selectin | 1 | 1996 | 42 | 0.010 |
Why?
|
| Smoking | 1 | 2001 | 1031 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 213 | 0.010 |
Why?
|
| Hippocampus | 1 | 2001 | 819 | 0.010 |
Why?
|
| Perfusion | 1 | 1996 | 200 | 0.010 |
Why?
|
| Bucladesine | 1 | 1995 | 19 | 0.010 |
Why?
|
| Iloprost | 1 | 1995 | 10 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2005 | 2591 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1997 | 316 | 0.010 |
Why?
|
| Diffusion | 1 | 1995 | 58 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1995 | 73 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 1996 | 287 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 1995 | 82 | 0.010 |
Why?
|
| Platelet Activation | 1 | 1995 | 70 | 0.010 |
Why?
|
| Blood | 1 | 1995 | 105 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 1995 | 120 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 2816 | 0.010 |
Why?
|
| Temperature | 1 | 1995 | 304 | 0.010 |
Why?
|
| Genotype | 1 | 2000 | 2539 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1419 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1996 | 577 | 0.010 |
Why?
|
| Aspirin | 1 | 1995 | 220 | 0.010 |
Why?
|
| Homeostasis | 1 | 1997 | 683 | 0.010 |
Why?
|
| Polymers | 1 | 1993 | 106 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2000 | 2529 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2001 | 3678 | 0.010 |
Why?
|
| Chemistry | 1 | 1987 | 60 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1987 | 85 | 0.000 |
Why?
|
| Pregnancy | 1 | 1997 | 7129 | 0.000 |
Why?
|
| Viscosity | 1 | 1982 | 35 | 0.000 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1981 | 6 | 0.000 |
Why?
|
| Hydrochloric Acid | 1 | 1981 | 14 | 0.000 |
Why?
|
| Sodium Hydroxide | 1 | 1981 | 7 | 0.000 |
Why?
|
| Potassium | 1 | 1982 | 280 | 0.000 |
Why?
|
| Phosphates | 1 | 1981 | 111 | 0.000 |
Why?
|
| Sodium | 1 | 1982 | 294 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1981 | 148 | 0.000 |
Why?
|
| HLA Antigens | 1 | 1981 | 243 | 0.000 |
Why?
|
| Leukemia | 1 | 1981 | 375 | 0.000 |
Why?
|